MAILING CERTIFICATE

hereby cereby that this correspondence is being deposited with the United States Postal Service with sufficient postage s first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington D.C. 20231 on

Date Signature

Kay Bulen

RECE

JUL 1 9 2001

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Clinton et al.

Filing Date:

February 16, 2000

Serial No.:

09/506,079

For:

HER-2 BINDING ANTAGONISTS

Art Unit:

1642

Examiner:

J. Hunt

Docket:

49321-16

Date:

11 July 2001

Box SEQUENCE

Assistant Commissioner for Patents

Washington, DC 20231

RESPONSE TO NOTICE TO COMPLY UNDER C.F.R. 1.821

Sir:

Applicants submit the attached Sequence Listing (under C.F.R. 1.821(c) and (e)) and Statement (under C.F.R. 1.821(f)), in response to the NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES, attached to the Office Communication, dated June 20, 2001. No new matter has been added.

Respectfully submitted,

Barry L. Davison

Attorney for Applicants Registration No. 47,309

Davis Wright Tremaine LLP 2600 Century Square 1501 Fourth Avenue Seattle, WA 98101-1688 Tel 206-628-7621 Fax 206-628-7699 F:\docs\49321\16\ResponsetoComply7-10-01.doc

1

Application No.: 09/506,079

TICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLECTION SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

X	1.	This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
	2.	This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
	3.	A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
X	4.	A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
	5	The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
	6.	The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
П	7.	Other:
ب		TECH CENTER ASSET
Applicant Must Provide:		
X	Α	n initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
X		n initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry ito the specification.
X	а	statement that the content of the paper and computer readable copies are the same and, where pplicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 825(b) or 1.825(d).
For questions regarding compliance to these requirements, please contact:		
Fo	r (te	Rules Interpretation, call (703) 308-4216 CRF Submission Help, call (703) 308-4212 ntln Software Program Support (SIRA)
	-	Technical Assistance703-308-6900 To Purchase Patentin Software703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE